Emerald Growth Investor holds a quantitatively derived Gold Morningstar Medalist Rating. The rating reflects that it has scored particularly well on factors Morningstar research associates with future outperformance relative to category peers.
Emerald Growth Fund Investor Class FFGRX
- NAV / 1-Day Return 23.80 / +0.51 %
- Total Assets 1.4B
-
Adj. Expense Ratio
1.080%
- Expense Ratio 1.130%
- Distribution Fee Level Average
- Share Class Type No Load
- Category Small Growth
- Investment Style Small Growth
- Min. Initial Investment 2,000
- Status Open
- TTM Yield 0.00
- Turnover 45%
USD | NAV as of Oct 02, 2026 | 1-Day Return as of Oct 02, 2026, 1:34 AM GMT+0
Morningstar’s Analysis FFGRX
Will FFGRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 21.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
F/m Emerald Life Sciences Innovation ETF | 6.36 | 91M | — |
Travere Therapeutics Inc Ordinary Shares | 2.06 | 30M | Healthcare |
InterDigital Inc | 2.05 | 30M | Technology |
AAR Corp | 1.85 | 27M | Industrials |
VSE Corp | 1.78 | 26M | Industrials |
Sensient Technologies Corp | 1.74 | 25M | Basic Materials |
Corcept Therapeutics Inc | 1.61 | 23M | Healthcare |
Axos Financial Inc | 1.51 | 22M | Financial Services |
Mercury Systems Inc | 1.51 | 22M | Industrials |
CECO Environmental Corp | 1.44 | 21M | Industrials |